博瑞醫藥(688166.SH)擬投資3億元於博瑞(山東)原料藥一期項目
格隆匯9月28日丨博瑞醫藥(688166.SH)公佈,為進一步擴充原料藥產能,滿足快速增長的市場需求,強化公司在原料藥環節的優勢地位,公司擬與山東省棗莊市嶧城區人民政府簽署《博瑞(山東)原料藥一期項目投資協議書》,項目佔地40畝,項目總投資約3億元人民幣。目標地塊精確位置及土地面積以乙方和政府土地管理部門簽署的《建設用地使用權出讓合同》為準。項目投資強度不低於280萬元/畝;項目全部達產後,綜合畝均税收不低於30萬元/年。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.